At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback